Share This Page
Vitamin K Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: Vitamin K
Market dynamics and patent landscape for Vitamin K drugs: exclusivity, Orange Book status, litigation risk, and generic entry
Vitamin K is a therapeutic class dominated by old, off-patent small-molecule actives with limited remaining coverage in the US. Market dynamics are driven by (1) inpatient use for reversal and bleeding prophylaxis, (2) shortages and supply reliability, (3) fixed pricing pressure in generics, and (4) residual value in newer delivery systems and narrow method-of-use claims where they exist. Across the main Vitamin K therapeutics, generic penetration is high and “new-to-market” patentable opportunity is concentrated in formulation, route-of-administration, and specific use regimens rather than the base compounds.
This landscape is anchored by the principal FDA-regulated Vitamin K actives: phytomenadione (vitamin K1), menadione (vitamin K3), and menaquinones (vitamin K2 forms in supplements, with far less relevance to US prescription exclusivity). Patent estates, where present, tend to be short and formulation-heavy; method-of-use exclusivity is less common and typically tied to specific administration protocols in regulated settings.
What Vitamin K drugs have patents in the US and what is their expiration risk?
Direct answer: For prescription vitamin K drugs with established brand histories, the US patent estates are mostly expired or near-expiry, with any remaining enforceable rights concentrated in later-expiring formulation and method-of-use patents rather than the core vitamin structure.
Which Vitamin K actives are most relevant to patent and exclusivity searches?
Core actives
- Phytomenadione (vitamin K1)
- Menadione (vitamin K3)
- Menaquinones (vitamin K2 forms) are generally marketed as supplements in many markets; US prescription exclusivity is less central.
Where patent protection tends to remain
-
Formulation patents
- Solubility and stability improvements for injectable or specialized dosage forms
- Emulsions, vehicles, and buffering systems that enable consistent bioavailability
-
Administration and dosing regimen patents
- Specific protocols for warfarin reversal or bleeding management
- Timing windows tied to INR targets
-
Manufacturing method claims
- Process controls for purity, particle size (if relevant), or sterile handling
Practical implication for market entry
If a firm is planning a generic or 505(j) product, the principal “action” usually sits with:
- Orange Book-listed patents that map to the exact listed drug product
- Narrow formulation patents that could trigger litigation if design-around is insufficient
- Any late-cycle Orange Book additions that extend exclusivity for specific NDA/ANDA pairs
What patents protect phytomenadione (vitamin K1) injection, tablets, and oral formulations?
Direct answer: Patent protection for phytomenadione products is typically tied to specific dosage forms and vehicles, not to the active itself. Remaining enforceable rights, when present, are usually Orange Book-listed formulation or method patents.
Patent estate pattern by dosage form
Injectables (high commercial relevance)
- Expect vehicle and stability claims to dominate if any patents remain
- Sterile manufacturing method patents are plausible in later families
Oral tablets/capsules
- Coverage tends to focus on:
- excipient systems
- dissolution characteristics
- modified-release designs (if any brand pursued them)
High-risk areas for generic entry
- If the branded product lists multiple Orange Book patents for the same NDA
- If there is a history of Paragraph IV litigation tied to that label
What patents protect menadione (vitamin K3) and why do they matter less for current US exclusivity?
Direct answer: Menadione products face a more limited modern brand landscape in the US, and any patent protection tends to be old, with generics frequently entrenched.
Where remaining claims would matter
- If there are still Orange Book listings tied to specific dosage forms
- If there are narrow dosing or manufacturing-method claims still within their term
Commercial takeaway
Menadione is less likely to create an active patent thicket than phytomenadione, given the smaller number of modern brand-originated prescription SKUs and the typical early expiration of legacy patents.
When does Vitamin K lose exclusivity in the US: Orange Book timelines and patent term windows
Direct answer: Most vitamin K prescription products are already outside active exclusivity and rely on generics for market share. Where patents remain, they are usually formulation or method-of-use claims with short remaining life.
Typical exclusivity and patent timelines to model
- Utility patents: term measured from earliest non-provisional filing subject to PTA and caps
- Orange Book-listed patents: bind generic challenge decision-making
- Delays from PTA: can extend enforcement by months to a few years, depending on prosecution history
How to assess “remaining exclusivity value” fast
- Count Orange Book-listed patents per listed drug
- Identify which are “Narrow” or tied to a formulation component
- Check whether a company has an existing ANDA with 505(j) relying on that NDA, which reduces the immediate need to litigate
What is the Orange Book status of Vitamin K drugs and which listed patents are most frequently challenged?
Direct answer: For most established vitamin K prescriptions, Orange Book entries are sparse in current practice and generics dominate. When Orange Book listings exist, formulation and method-of-use patents are the main challenge targets.
Patent listing types that drive Paragraph IV risk
- “Composition” claims are less common in vitamin K families once the active itself is long known
- “Formulation” claims are the practical targets for generics seeking to certify/design around
- “Method of use” claims are relevant if the branded label has a distinctive clinical protocol
Generic certification implications
- If a generic can comply without infringing a listed formulation patent, it can pursue a simpler pathway
- If it cannot, Paragraph IV becomes the driver of delays and settlements
How many patents cover each vitamin K brand and what is the “patent thicket” level?
Direct answer: The thicket level for Vitamin K prescriptions is generally low to moderate, with coverage concentrated in a small number of later families rather than sprawling line extensions.
What to count in the patent estate model
- Number of Orange Book-listed patents per NDA/Listed Drug
- Number of distinct claim types (formulation vs method vs manufacturing)
- Whether patents share the same earliest priority date (family clustering)
Typical outcomes by thicket level
- Low thicket: rapid generic uptake, limited settlement dynamics
- Moderate thicket: sporadic litigation tied to specific formulations
- High thicket: uncommon for vitamin K products unless there is a modern branded reformulation strategy
What patent litigation affects Vitamin K generics and biosimilars?
Direct answer: Vitamin K is small-molecule therapy. Biosimilars are not applicable to the vitamin K class as a category framing. Litigation risk exists mainly in generic drug patent disputes tied to Orange Book-listed patents for specific dosage forms.
Litigation drivers
- Delayed approvals from Paragraph IV challenges
- Settlements that create a carve-out window for the first generic entrant
- Design-around disputes in formulation and dosing
Biosimilar risk assessment
- Not applicable to vitamin K as a class, since it is not a biologic drug category.
How do Vitamin K drugs compare on patent strength: phytomenadione vs menadione
Direct answer: Phytomenadione (vitamin K1) generally has a larger prescription footprint and more plausible remaining formulation coverage, while menadione coverage is typically older and less likely to sustain an active patent estate.
Patent-strength scoring rubric (practical)
- Remaining patent term (earliest and latest family expirations)
- Orange Book depth per NDA
- Likelihood of design-around (vehicle and administration-specific constraints)
- Historical litigation or settlements (if any)
What delivery forms are most likely to be protected by formulation patents?
Direct answer: Injectable and specialized oral delivery forms are the most likely to have surviving formulation IP, because they address stability, solubility, and dosing reliability.
Dosage forms to prioritize in an IP watch
- IV/IM formulations of phytomenadione
- Any brand-specific oral systems (if modified release exists)
- Any “unit-of-use” packaging that is not only regulatory but tied to formulation claims
What generic entry risks exist for Vitamin K products?
Direct answer: Entry risk is mainly patent-listing driven for the exact branded formulation, not active-molecule novelty. The largest risk arises when generics cannot design around a formulation patent while still meeting the branded label, bioavailability expectations, and excipient constraints.
Entry risk checklist
- Confirm the marketed formulation’s listed patents in the Orange Book for that exact dosage form
- Map the generic’s proposed excipients and vehicle to formulation claim elements
- Evaluate whether the label’s dosing regimen implicates method-of-use claims
- Review whether prior generic entries occurred and whether settlements created delayed launch dates
What regulatory exclusivities apply to Vitamin K: 5-year, 3-year, and orphan-style protections?
Direct answer: Vitamin K class products are generally mature, so regulatory exclusivities (new chemical entity, new dosage form, new clinical investigation) are typically not active in current cycles. Any exclusivity remaining would be tied to a specific modern NDA or reformulated product.
Real-world effect
- Most vitamin K brand products in the US do not carry active regulatory exclusivity, shifting the battlefield to patents.
Which companies hold the most relevant IP positions for Vitamin K drugs?
Direct answer: The most relevant IP positions usually belong to originators of branded injectable formulations and to firms that acquired or developed later reformulations. In practice, generic entrants dominate commercialization where patents have expired.
How to identify the controlling IP entities (how professionals operationalize it)
- Start from the Orange Book “NDA holder” and “patent holder” fields for each listed drug
- Trace assignment history for late-cycle patents (continuations, divisionals)
- Link to litigation counsel filings to identify true enforcement entities
Market dynamics for Vitamin K: pricing, supply, and tender-driven demand
Direct answer: Vitamin K demand is concentrated in hospitals and institutional settings, where procurement is driven by tender pricing, supply continuity, and inventory reliability. Generic competition drives price compression once patent barriers clear.
Demand characteristics that shape commercialization
- Inpatient bleeding management and warfarin reversal workflows
- Prophylaxis in specific patient groups
- Stocking and substitution constraints that can slow switch even after patents expire
Supply and shortage sensitivity
- When shortages occur, contracted suppliers can retain temporary share regardless of patent status.
- Once supply stabilizes, price becomes the dominant driver.
What licensing deals and settlements shape the Vitamin K generic timeline?
Direct answer: Settlement dynamics are typically modest and time-bounded for Vitamin K because the patent estate depth is usually limited. Where Paragraph IV disputes exist, settlements more often reflect narrow formulation and product-specific outcomes than broad class settlements.
What to look for in settlement patterns
- Launch timing tied to dismissal or covenant not to sue
- Carve-outs for specific dosage strengths or package sizes
- Licensing limited to a defined formulation “field of use”
Key Takeaways
- Vitamin K (phytomenadione and menadione) is a mature small-molecule class with limited remaining exclusivity value in the US.
- Patent coverage, where enforceable, is concentrated in formulation, vehicle/stability, and sometimes method-of-use claims tied to specific dosage forms rather than the underlying vitamin structure.
- Generic entry risk is driven by Orange Book-listed patents for the exact NDA strength and dosage form, not by broad “Vitamin K” active ingredient novelty.
- Biosimilar litigation is not a factor for vitamin K; litigation risk is generic-to-brand patent dispute focused on Paragraph IV and settlement-driven launch timing.
- Market dynamics favor generic price compression after clearance, but supply continuity and institutional tendering can sustain brand share temporarily.
FAQs
1) What is the main IP barrier for generic phytomenadione injection in the US?
Usually formulation and/or manufacturing method patents listed in the Orange Book for the specific injectable product and strength, plus any method-of-use claims tied to administration protocols.
2) Can a generic launch Vitamin K tablets without a Paragraph IV challenge?
Often yes if no Orange Book-listed patents remain that cover the specific tablet formulation strength and excipient/vehicle elements, but the decision turns on the exact listed drug and patent mapping.
3) Do Vitamin K supplements have pharmaceutical patent risks comparable to prescription drugs?
Typically not in the same Orange Book-driven way, since supplements are not regulated through the NDA/ANDA system and rarely create enforceable exclusivity comparable to prescription products.
4) What usually triggers a late Orange Book patent addition for vitamin K products?
Continuation filings, PTA-related patent term adjustments, or patent reclassification after litigation strategy shifts, but the practical impact is localized to specific dosage forms.
5) How does hospital formulary behavior affect generic uptake for Vitamin K?
Switching depends on procurement contracts, stocking practices, substitution permissions, and supply stability. Patent expiry alone does not guarantee immediate share loss.
References
- FDA. “Drugs@FDA: FDA Approved Drug Products.” U.S. Food and Drug Administration.
- FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
- U.S. Patent and Trademark Office (USPTO). “Patent Term, Patent Adjustment, and Patent Prosecution Basics.” USPTO.
More… ↓
